Abstract
From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.
| Original language | English |
|---|---|
| Pages (from-to) | 305-315 |
| Number of pages | 11 |
| Journal | Clinical Neurology |
| Volume | 51 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2011 |
Fingerprint
Keywords
- Acute ischemic stroke
- Ischemic cell death
- Neuroprotection
- Therapeutic time window
- Thrombolysis
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection. / Kamiya, Tatsushi; Abe, Koji.
In: Clinical Neurology, Vol. 51, No. 5, 05.2011, p. 305-315.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection
AU - Kamiya, Tatsushi
AU - Abe, Koji
PY - 2011/5
Y1 - 2011/5
N2 - From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.
AB - From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.
KW - Acute ischemic stroke
KW - Ischemic cell death
KW - Neuroprotection
KW - Therapeutic time window
KW - Thrombolysis
UR - http://www.scopus.com/inward/record.url?scp=79959458284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959458284&partnerID=8YFLogxK
U2 - 10.5692/clinicalneurol.51.305
DO - 10.5692/clinicalneurol.51.305
M3 - Article
C2 - 21706826
AN - SCOPUS:79959458284
VL - 51
SP - 305
EP - 315
JO - Clinical Neurology
JF - Clinical Neurology
SN - 0009-918X
IS - 5
ER -